All AbMole products are for research use only, cannot be used for human consumption.
Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation.
| CAS Number | 1418205-77-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
[3] Egídio Freitas, et al. Drugs. Bimekizumab for the Treatment of Psoriasis
[4] Kristian Reich, et al. N Engl J Med. Bimekizumab versus Secukinumab in Plaque Psoriasis
[5] Richard B Warren, et al. N Engl J Med. Bimekizumab versus Adalimumab in Plaque Psoriasis
| Related IL Receptor/Related Products |
|---|
| IL-15-IN-1
IL-15-IN-1 is a potent and selective Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells with an IC50 of 0.8 μM. |
| IL-17 modulator 3
IL-17 modulator 3 is an IL-17 modulator. |
| IL-17 modulator 4
IL-17 modulator 4 is a proagent of IL-17 modulator 1. |
| IL-17A modulator-3
IL-17A modulator-3 is a IL-17A modulator. |
| IL-17 modulator 4 sulfate
IL-17 modulator 4 sulfate is a proagent of IL-17 modulator 1. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
